Navigation Links
Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Date:4/3/2008

- Company to present interim results from phase 2 trial of novel compound

RX-1741 -

NEW HAVEN, Conn., April 3, 2008 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that Albert Collinson, Ph.D., Chief Business Officer, will be presenting at the 10th Annual Superbugs & Superdrugs Conference on April 9, 2008 in London, UK. Dr. Collinson will disclose interim results from Rib-X's Phase 2 clinical trial of RX-1741 in the treatment of uncomplicated skin and soft tissue infections (uSSTI).

RX-1741 was discovered using Rib-X's proprietary computational tools and knowledge of the three dimensional structure of the 50S subunit of the ribosome. An oxazolidinone antibiotic that exhibits activity against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, RX-1741 has demonstrated both wider spectrum and stronger potency of activity than Zyvox(R) (linezolid), the only currently marketed product in this compound class.

uSSTI Study Design

The uSSTI study is a Phase 2, multicenter, randomized, open-label, comparative study to evaluate the safety and efficacy of RX-1741 versus linezolid in the outpatient treatment of adults with uSSTI. The study assesses the efficacy, safety and tolerability of a once or twice daily dose of RX-1741 compared to a twice-daily dose of linezolid. Dosing is given for five to ten days for the treatment of ambulatory patients with uSSTI.

The uSSTI study will enroll approximately 150 patients in study centers across the US. The Company intends to release final data from all patients during the first half of 2008.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community-acquired and hospital-acquired pathogens. The Company's integrated research strategy, which combines state of the art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the RX-1741 designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the RX-3341 program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin-resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these programs is focused on design and development of an orally active macrolide for community use for treatment of skin infections, including those caused by MRSA. The second discovery program is directed towards identifying a new chemical class of antibiotics active against multi-drug resistant Gram negative bacteria.

For more information on the ribosome and the Rib-X mission, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- Hearing protection devices refer to the barriers that ... inner ear. Hearing protection devices include earplugs, uniform attenuation ... for users exposed to noise levels of over 80 ... are inserted in the ear canal to protect the ... natural sound perception with the help of acoustic filters. ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016  Increasingly, health ... monitoring their vital signs with wireless technology. With the ... can automate patient oversight and remotely detect problems before ... vital signs across in-hospital environments. the ... the United States . --> ...
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism and Related ... autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering autism treatment ... is key to providing effective treatment for individuals with ASD. Now, over 1,800 ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, ... move workloads to the cloud. Cirracore provides a secure VMware® vCloud Air ... the Internet. Transformation Solutions (TSL Partners) provides a full range of services ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... therapy products, announced today the introduction of the newly designed, innovative shoulder wrap. ... and better cold therapy coverage for the injured arm and shoulder to promote ...
(Date:2/9/2016)... ... 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro ... is a newly patented product that has solved some of the basic problems golfers have ... morning dew or right after a rain shower, might understand the struggle of placing the ...
Breaking Medicine News(10 mins):